Skip to main content

Day: July 18, 2024

Eviden supports the University of Reims Champagne-Ardenne (URCA) in its move towards quantum computing

Press release Eviden supports the University of Reims Champagne-Ardenne (URCA) in its move towards quantum computing Paris, France – July 18th, 2024 – Eviden, the Atos Group business leading in digital, cloud, big data and security, today announced it is supporting the University of Reims Champagne-Ardenne (URCA) through training initiatives to raise awareness of the challenges of quantum computing. URCA will draw on Eviden’s long-standing expertise in the sector, through its Qaptiva offering. While some sectors seem ready to turn to quantum computing for problems now handled by supercomputers, customers’ objectives are changing. Demand is shifting from pure research to the development and use of concrete quantum computing applications, in anticipation of the arrival of the first quantum computers. The University...

Continue reading

Share Buyback Transaction Details July 11 – July 17, 2024

PRESS RELEASE                                         Share Buyback Transaction Details July 11 – July 17, 2024 Alphen aan den Rijn – July 18, 2024 – Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 119,272 of its own ordinary shares in the period from July 11, 2024, up to and including July 17, 2024, for €18.3 million and at an average share price of €153.10. These repurchases are part of the share buyback program announced on February 21, 2024, under which we intend to repurchase shares for €1 billion during 2024. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2024Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2024...

Continue reading

WTW announces appointment of Eric Latalladi as Global Head of Technology

NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, today announced the appointment of Eric Latalladi as WTW Global Head of Technology, effective July 22, 2024. Alexis Faber, Chief Operating Officer, commented, “I am delighted that Eric is joining WTW and taking on the role of Global Head of Technology. Eric is a seasoned leader with over 25 years of technology experience and has a proven track record of enabling growth, demonstrating value, and driving and sustaining change. We’ve made tremendous progress in transforming and simplifying to grow over the last three years, and with Eric’s direction we’ll take WTW Technology into the next phase of its exciting future.”  Speaking about his appointment, Latalladi said, “I am excited about the future of WTW Technology...

Continue reading

DSV, 1122 – CONCLUSION OF SHARE BUYBACK PROGRAMME IN DSV A/S

Company Announcement No. 1122 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. The share buyback programme announced has now been concluded. The programme has been carried out in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules.Trading day Number of shares bought back   Average transaction price   Amount DKK             Accumulated trading for days 1-54 890,100   1,059.06   942,667,25555: 15 July 2024 15,000   1,170.69   17,560,35056: 16 July 2024 15,000   1,156.60   17,349,00057: 17 July 2024 19,500   1,145.28   22,332,960Accumulated trading for days 1-57 939,600   1,064.19   999,909,565After the disclosed...

Continue reading

Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine

EMA will now initiate its centralized review procedure under accelerated assessment for Bavarian Nordic’s chikungunya vaccineCOPENHAGEN, Denmark, July 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA), which was submitted in June 2024 for CHIKV VLP, the Company’s vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. Validation of the application confirms the submission is complete and begins the EMA’s centralized review procedure under accelerated assessment. The accelerated assessment, which was granted by EMA’s Committee for Medicinal Products for Human Use (CHMP) in February 2024, aims to reduce the timeframe for the CHMP to review a MAA, potentially...

Continue reading

LIFT To Acquire Shorty West Lithium Claim

VANCOUVER, British Columbia, July 18, 2024 (GLOBE NEWSWIRE) — Li-FT Power Ltd. (“LIFT” or the “Company”) (TSXV: LIFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to announce that it has entered into a mineral property purchase agreement dated July 17 2024 with Infinity Stone Ventures Corp. (CSE: GEMS) to acquire the Shorty West Lithium mineral claim (the “Shorty West Claim”), which is adjacent to the Company’s Yellowknife Lithium Project. As consideration for the Shorty West Claim, the Company will issue 12,000 common shares, which will be subject to applicable resale restrictions under Canadian securities laws. The completion of the acquisition is subject to the approval of the TSX Venture Exchange. No finder’s fees are payable in connection with the acquisition.Figure 1 – Location of Infinity Stone Venture’s Shorty West mineral...

Continue reading

Innofactor Plc’s Half-Yearly Report for January 1–June 30, 2024 (IFRS)

Innofactor Plc Half-Yearly Report July 18, 2024, at 9:00 Finnish time In a challenging market situation, Innofactor fell short of its targets in the second quarter, and profitability was also significantly further reduced by legal expenses. April–June 2024 in brief:Net sales were approximately EUR 19.9 million (2023: 20.1), representing a decrease of 1.1% The operating margin was approximately EUR 0.6 million (2023: 1.8), representing a decrease of 65.8%The operating margin includes legal expenses of approximately EUR 0.75 million, without which the operating margin would have amounted to EUR 1.4 million and the comparable change would have been a decrease of 23.2%Operating profit was EUR -0.1 million (2023: 1.0), representing a decrease of 114.5%The operating profit includes the corresponding legal expenses as the operating...

Continue reading

Aspocomp’s Half-Year Report 2024: Net sales and operating result decreased in the second quarter, orders received turned to growth

Aspocomp Group Plc, Half-Year Report, July 18, 2024, at 9:00 a.m. (Finnish time) SECOND QUARTER 2024 HIGHLIGHTSNet sales EUR 7.0 (9.5) million, decrease of 26% Operating result EUR -1.2 (0.4) million, -17.5% (4.2%) of net sales Earnings per share EUR -0.19 (0.05) Operative cash flow EUR -1.1 (-0.6) million Orders received EUR 6.6 (5.4) million, increase of 22% Equity ratio 57.8% (67.9%)JANUARY-JUNE 2024 HIGHLIGHTSNet sales EUR 13.3 (18.4) million, decrease of 28% Operating result EUR -2.8 (0.7) million, -21.4% (4.0%) of net sales Earnings per share EUR -0.44 (0.09) Operative cash flow EUR -3.1 (0.9) million Orders received EUR 14.2 (19.1) million, decrease of 26% Order book at the end of the review period EUR 11.3 (15.0) million, decrease of 25% Equity ratio 57.8% (67.9%)OUTLOOK FOR 2024 Inflation and interest rates,...

Continue reading

Inventiva announces a €20.1 million issuance of royalty certificates

Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng). Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term. Cash runway extended through September 2024 and evaluation of strategic and financing options pursued1.Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced...

Continue reading

Company announcement no 14/2024 – June 2024 Sales price

June 2024 Sales price Group sales prices development as followsQ1           2017       1,24 EUR/kg live weight (Jan 1,23 EUR – Feb 1,24 EUR – Marts 1,26 EUR) Q2           2017       1,41 EUR/kg live weight (Apr 1,43 EUR – May 1,41 EUR – June 1,39 EUR) Q3           2017       1,30 EUR/kg live weight (July 1,32 EUR – Aug 1,30 EUR – Sept 1,29 EUR) Q4           2017       1,13 EUR/kg live weight (Oct 1,17 EUR – Nov 1,12 EUR – Dec 1,11 EUR) Q1           2018       1,09 EUR/kg live weight (Jan 1,07 EUR – Feb 1,08 EUR – Marts 1,12 EUR) Q2           2018       1,17 EUR/kg live weight (April 1,18 EUR – May 1,15 EUR – June 1,18 EUR) Q3           2018       1,19 EUR/kg live weight (July 1,19 EUR, August 1,18 EUR, September 1,19) Q4           2018       1,10 EUR/kg live weight (Oct 1,11 EUR – Nov 1,12 EUR – Dec 1,07 EUR) Q1           2019      ...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.